Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Obesity; diabetes

Glucagon-like peptide-1 receptor (GLP-1R; GLP1R); glucagon receptor (GCGR); glucose-dependent insulinotropic polypeptide receptor (GIP receptor)

Mouse studies suggest peptides that agonize GLP1R, GCGR and GIP receptor could be used to treat obesity and diabetes. In a mouse model of obesity with diabetes or in mice fed a high-fat diet, a peptide that activated all three receptors decreased plasma glucose levels and increased insulin levels after glucose challenge compared with peptide hormones for individual receptors. In the high-fat diet-fed model, the peptide induced weight loss and decreased overall glucose exposure compared with saline. Next steps could include optimizing the pharmacology of the peptide.
At least six companies market agonists for GLP1R and GCGR to treat cardiovascular or endocrine/metabolic disease.

SciBX 6(48); doi:10.1038/scibx.2013.1390
Published online Dec. 19, 2013

Patent and licensing status unavailable

Gault, V.A. et al. J. Biol. Chem.;
published online Oct. 28, 2013;
doi:10.1074/jbc.M113.512046
Contact: Nigel Irwin, University of Ulster, Londonderry, U.K.
e-mail:
n.irwin@ulster.ac.uk